Clinical Trials
19 trialsNCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06271837 2026-05-11
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
AstraZeneca
Phase 2 Active not recruiting
NCT07318805 2026-05-08
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Recruiting
NCT04158258 2026-04-23
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
Hoffmann-La Roche
Active not recruiting
NCT04732598 2026-04-21
AMBITION
Japanese Foundation for Cancer Research
Phase 3 Completed
NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT05769010 2026-04-01
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Henan Cancer Hospital
Phase 2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06976944 2026-02-23
PRELUDE
Japanese Foundation for Cancer Research
Phase 2 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT05180006 2025-12-01
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT02436993 2025-07-14
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
Phase 2 Active not recruiting
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting